Marble Harbor Investment Counsel LLC Sells 1,873 Shares of Johnson & Johnson $JNJ

Marble Harbor Investment Counsel LLC decreased its stake in shares of Johnson & Johnson (NYSE:JNJ – Free Report) by 3.4% during the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 52,556 shares of the company’s stock after selling 1,873 shares during the period. Johnson & Johnson makes up 1.3% of Marble Harbor Investment Counsel LLC’s portfolio, making the stock its 23rd biggest position. Marble Harbor Investment Counsel LLC’s holdings in Johnson & Johnson were worth $13,914,000 as of its most recent filing with the Securities and Exchange Commission.

Several other large investors have also recently bought and sold shares of JNJ. Wellington Management Group LLP lifted its stake in shares of Johnson & Johnson by 12.5% in the 2nd quarter. Wellington Management Group LLP now owns 22,588,696 shares of the company’s stock worth $5,736,851,000 after acquiring an additional 2,513,321 shares during the period. Deutsche Bank AG increased its stake in shares of Johnson & Johnson by 8.5% during the second quarter. Deutsche Bank AG now owns 15,661,323 shares of the company’s stock valued at $3,977,506,000 after acquiring an additional 1,225,676 shares during the period. Fisher Asset Management LLC increased its stake in shares of Johnson & Johnson by 11.5% during the third quarter. Fisher Asset Management LLC now owns 14,837,126 shares of the company’s stock valued at $3,927,981,000 after acquiring an additional 1,530,070 shares during the period. Amundi increased its stake in shares of Johnson & Johnson by 17.5% during the first quarter. Amundi now owns 13,406,820 shares of the company’s stock valued at $3,277,163,000 after acquiring an additional 2,001,139 shares during the period. Finally, Jupiter Topco LLC bought a new stake in Johnson & Johnson during the second quarter worth approximately $1,967,399,000. Institutional investors and hedge funds own 69.55% of the company’s stock.

Johnson & Johnson Stock Performance

NYSE:JNJ opened at $283.69 on Friday. The company has a 50-day moving average of $266.83 and a 200-day moving average of $249.54. The firm has a market cap of $682.93 billion, a price-to-earnings ratio of 42.98, a price-to-earnings-growth ratio of 2.77 and a beta of 0.22. The company has a current ratio of 1.02, a quick ratio of 0.74 and a debt-to-equity ratio of 0.44. Johnson & Johnson has a twelve month low of $193.45 and a twelve month high of $286.08.

Johnson & Johnson (NYSE:JNJ – Get Free Report) last released its earnings results on Tuesday, October 13th. The company reported $2.59 EPS for the quarter, topping analysts’ consensus estimates of $2.53 by $0.06. Johnson & Johnson had a net margin of 16.20% and a return on equity of 31.64%. The business had revenue of $25.40 billion for the quarter, compared to the consensus estimate of $25.38 billion. During the same period in the previous year, the firm earned $2.80 EPS. The business’s revenue for the quarter was up 5.9% on a year-over-year basis. Johnson & Johnson has set its FY 2026 guidance at 11.050-11.150 EPS. Analysts forecast that Johnson & Johnson will post 11.12 earnings per share for the current fiscal year.

Johnson & Johnson Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, December 8th. Shareholders of record on Tuesday, November 24th will be given a $1.34 dividend. The ex-dividend date is Tuesday, November 24th. This represents a $5.36 annualized dividend and a yield of 1.9%. Johnson & Johnson’s payout ratio is 81.21%.

Insider Activity at Johnson & Johnson

In other news, EVP Timothy Schmid sold 33,597 shares of the stock in a transaction on Wednesday, September 2nd. The stock was sold at an average price of $274.74, for a total transaction of $9,230,439.78. Following the completion of the sale, the executive vice president owned 25,447 shares in the company, valued at approximately $6,991,308.78. This represents a 56.90% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, EVP Jennifer L. Taubert sold 15,000 shares of the firm’s stock in a transaction on Monday, August 17th. The stock was sold at an average price of $263.36, for a total value of $3,950,400.00. Following the sale, the executive vice president directly owned 194,451 shares of the company’s stock, valued at approximately $51,210,615.36. This represents a 7.16% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders own 0.16% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of research firms have weighed in on JNJ. Morgan Stanley cut their target price on Johnson & Johnson from $294.00 to $292.00 and set an “overweight” rating for the company in a research report on Thursday, October 15th. Wall Street Zen cut Johnson & Johnson from a “buy” rating to a “hold” rating in a research report on Saturday, August 1st. Scotiabank reiterated an “outperform” rating and set a $305.00 price target on shares of Johnson & Johnson in a research report on Thursday, July 16th. Weiss Ratings downgraded Johnson & Johnson from a “buy (b+)” rating to a “buy (b-)” rating in a research note on Friday, October 23rd. Finally, Sanford C. Bernstein set a $270.00 price objective on Johnson & Johnson in a report on Thursday, October 15th. One equities research analyst has rated the stock with a Strong Buy rating, seventeen have issued a Buy rating and eight have assigned a Hold rating to the company. Based on data from MarketBeat, Johnson & Johnson presently has an average rating of “Moderate Buy” and a consensus target price of $275.92.

Check Out Our Latest Analysis on JNJ

Key Johnson & Johnson News

These are some of the JNJ news items that stood out recently:

Johnson & Johnson Company Profile

(Free Report)

Johnson & Johnson is a global healthcare company that develops and sells prescription medicines and medical technologies. Its business is organized around two segments: Innovative Medicine and MedTech. Innovative Medicine develops treatments in areas including oncology, immunology, neuroscience, cardiovascular and metabolic disease, and pulmonary hypertension. MedTech provides products and technologies for fields such as surgery, orthopedics, and vision care. Founded in 1886, Johnson & Johnson serves patients and healthcare professionals in markets around the world.

Featured Articles

Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ – Free Report).

Institutional Ownership by Quarter for Johnson & Johnson (NYSE:JNJ)

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.